Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20558074 | 0.89 | P2RY12 (0.48) | ADORA3BMPR1BADORA2AADORA2BP2RY12 | |
| SCHEMBL13974841 | 0.89 | ADORA2A (0.58) | ADORA3ADORA2AADORA2B | |
| SCHEMBL13964749 | 0.89 | ADORA2A (0.58) | ADORA3ADORA2AADORA2B | |
| SCHEMBL19190143 | 0.89 | ADORA2A (0.58) | ADORA3ADORA2AADORA2B | |
| SCHEMBL13964740 | 0.89 | ADORA2A (0.58) | ADORA3ADORA2AADORA2B | |
| SCHEMBL25496185 | 0.88 | BMPR1B (0.53) | ADORA3BMPR1BADORA2AADORA2BP2RY12 | |
| SCHEMBL26297894 | 0.88 | BMPR1B (0.53) | ADORA3BMPR1BADORA2AADORA2BP2RY12 | |
| SCHEMBL21063207 | 0.87 | LMNA (0.60) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL9294393 | 0.87 | LMNA (0.60) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL21625242 | 0.87 | LMNA (0.60) | ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638716-B2 | Compounds, compositions, and methods for the treatment of disease | F-star Therapeutics, Inc. (GB) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638716-B2 | Compounds, compositions, and methods for the treatment of disease | STING1, MAVS, IRF3 | ADORA3 1586/4885BMPR1B 889/4885ADORA2A 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.